




Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma



MONDAY, OCTOBER 12, 2026 | VIENNA, AUSTRIA

10:00 – 10:05 **WELCOME**

10:05 – 11:05 **ROLE OF IMMUNOTHERAPY IN MM**

Chairs: Martin Gramatzki, Sebastian Theurich, Katja Weisel

10:05 – 10:15 **Frontline Therapy 2026**

Katja Weisel

10:15 – 10:25 **Role of Belamaf in 2026 and in the Future**

Christof Scheidt

10:25 – 10:35 **Managing short-term TCE/CAR T cell toxicities – what did we learn?**

Marc Raab

10:35 – 10:45 **Late neurotoxicity after CAR T**

Sophia Kadel

10:45 – 10:55 **Vaccination post CAR T cell therapy: Facts and Expert Opinions**

Heinz Ludwig

10:55 – 11:05 **Panel Discussion**

11:05 – 12:15 **HOW TO OPTIMIZE T CELL ENGAGING THERAPIES**

Chairs: Hartmut Goldschmidt, Hans Salwender, Annamaria Brioli

11:05 – 11:15 **How to administer best T cell engaging antibodies – weekly, biweekly, monthly; fixed duration?**

Jan Krönke

11:15 – 11:25 **How to address EMD with T cell engaging therapies? Role of CelMoDs?**

Monika Engelhardt

11:25 – 11:35 **Mechanisms of resistance to T cell engaging antibodies**

Niels Weinhold

11:35 – 11:45 **Should we measure Ag expression or screen for T cell functionality – how and when?**

Leo Rasche

11:45 – 11:55 **Treatment of relapse after CAR T**

Lisa Leypoldt

11:55 – 12:15 **Panel Discussion**

12:15 – 12:50 **BREAK**

12:50 – 2:00	THE FUTURE OF T CELL ENGAGING THERAPIES <i>Chairs: Matthias Auer, Maria Krauth, Cyrus Khandanpour</i>
12:50 – 1:00	CAR-T in earlier lines: For everyone or for functional high-risk? Elias Mai
1:00 – 1:10	Optimal Bridging strategies: What to do, what to avoid? Is Talquetamab an option? Selinexor? Melflufen? Martin Kortüm
1:10 – 1:20	CAR-T after CAR-T? Possible? Feasible? Effective? Ralph Wäsch
1:20 – 1:30	PI Therapy 2.0 - Can we apply Proteasome Inhibition to modulate Target Antigen expression and efficacy of T cell redirection strategies? Florian Bassermann
1:30 – 1:40	Novel constructs/concepts – Dual binding CAR-T cells, in vivo CART cells Michael Hudecek
1:40 – 2:00	Panel Discussion and close